Heather A. Parsons

Oncology

825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.

Journal: medRxiv : the preprint server for health sciences

Published: July 30, 2026

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 16, 2026

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

Journal: JAMA oncology

Published: June 25, 2026

Circulating Tumor DNA in Early Breast Cancer: A Review.

Circulating Tumor DNA in Early Breast Cancer: A Review.

Journal: JAMA oncology

Published: May 28, 2026

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 10, 2026

Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias.

Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias.

Journal: EBioMedicine

Published: March 04, 2026

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 19, 2026

MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy.

MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy.

Journal: Clinical chemistry

Published: February 09, 2026

Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.

Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.

Journal: The Journal of clinical investigation

Published: January 14, 2026

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

Journal: JAMA oncology

Published: December 18, 2025

MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy.

MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes.

Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes.

Journal: medRxiv : the preprint server for health sciences

Published: September 15, 2025

Showing 1-12 of 79

Last Updated: 09/26/2026